Fragile X Syndrome

1. Disease Information

1.1 Overview

FXS is characterized by a broad phenotype including developmental delay, intellectual disability, behavioral dysregulation (anxiety, hyperactivity/ADHD traits, aggression), autistic features, and a set of physical findings (e.g., macroorchidism in males after puberty). (de2025fromdiscoveryto pages 4-6, de2025fromdiscoveryto pages 3-4)

1.2 Key identifiers and synonyms (available from retrieved sources)

• OMIM: 300624 (ciaccio2017fragilexsyndrome pages 1-2)
• Gene: FMR1; locus Xq27.3 (ciaccio2017fragilexsyndrome pages 1-2)
• Common synonym: Martin–Bell syndrome (ciaccio2017fragilexsyndrome pages 1-2)

ICD-10/ICD-11, MeSH, Orphanet/ORPHAcode: Not extractable from the retrieved documents; these need direct retrieval from ICD and Orphanet/MeSH resources.

1.3 Data provenance

The information summarized here is derived from aggregated disease-level resources (peer-reviewed reviews and clinical trial publications), plus primary studies (e.g., population newborn screening study; interventional trials). (berrykravis2024effectsofafq056 pages 1-2, seng2024longitudinalfollowupof pages 1-2, coffee2009incidenceoffragile media 983b62aa)

1.4 Compact identifiers/threshold summary

Table: This table summarizes the core identifiers, synonyms, prevalence figures, and CGG repeat thresholds for Fragile X syndrome from key review sources. It is useful as a compact normalization reference for disease knowledge-base curation.

2. Etiology

2.1 Disease causal factors

Primary cause: A CGG repeat expansion in the 5′UTR of FMR1. Commonly used thresholds across sources: - Normal: ~5–55 repeats (or 5–44 in some classification) (de2025fromdiscoveryto pages 4-6, ciaccio2017fragilexsyndrome pages 1-2) - Premutation: 55–200 repeats (de2025fromdiscoveryto pages 4-6, genovese2025systematicreviewfragile pages 2-4) - Full mutation (FXS): >200 repeats, associated with hypermethylation/silencing and loss of FMRP (de2025fromdiscoveryto pages 4-6, genovese2025systematicreviewfragile pages 2-4)

Mechanistically, when repeat length exceeds ~200, methylation and chromatin changes (histone deacetylation, heterochromatin formation) contribute to transcriptional silencing and loss of FMRP. (volianskis2024alterationsinsynaptic pages 15-19)

Less common molecular causes: Non-repeat FMR1 alterations such as deletions/duplications and SNVs account for <1% of molecular diagnoses in one review. (ciaccio2017fragilexsyndrome pages 1-2)

2.2 Risk factors

• Sex: males are generally more severely affected due to having a single X chromosome. (genovese2025systematicreviewfragile pages 2-4)
• Repeat instability/anticipation: expansion from premutation to full mutation occurs predominantly during maternal transmission (anticipation). (genovese2025systematicreviewfragile pages 2-4, volianskis2024alterationsinsynaptic pages 15-19)

2.3 Protective factors

No specific genetic or environmental “protective factors” were identified within the retrieved evidence corpus. However, mosaicism (cells with smaller/unmethylated alleles) is associated with better cognitive outcomes, implying partial protection at the molecular/cellular level. (genovese2025systematicreviewfragile pages 7-9)

2.4 Gene–environment interactions

The retrieved corpus did not provide specific, well-supported gene–environment interaction claims for classic FXS.

3. Phenotypes

3.1 Core neurodevelopmental phenotype

• Intellectual disability / cognitive impairment: core feature; one review reports typical IQ <70 with male average ~40–55 and female ~65–70. (de2025fromdiscoveryto pages 3-4)
• ASD/autistic features: common; ~30–50% of males and ~20% females have autistic behaviors by direct assessment in one review (de2025fromdiscoveryto pages 3-4); a systematic review reports comorbid ASD in “just over 40%” overall (46% males, 16% females). (genovese2025systematicreviewfragile pages 7-9)
• Behavioral features: hyperactivity, anxiety, aggression, attention deficits, sensory hyperarousal; ADHD criteria frequently met. (de2025fromdiscoveryto pages 3-4)

3.2 Neurologic comorbidity

• Seizures: estimates include ~15–20% of males and ~5% of females (de2025fromdiscoveryto pages 4-6) and 10–20% of boys and 5–10% of girls (ciaccio2017fragilexsyndrome pages 2-3).
• EEG abnormalities: ~74–75% of young children show EEG abnormalities; ~1/3 remit by mid-childhood in one systematic review. (genovese2025systematicreviewfragile pages 7-9)

3.3 Physical phenotype and medical comorbidities (examples with frequency where available)

• Macroorchidism: 63–95% (males) (ciaccio2017fragilexsyndrome pages 2-3)
• Obesity: 53–61% (ciaccio2017fragilexsyndrome pages 2-3)
• Recurrent otitis media: 47–97% (ciaccio2017fragilexsyndrome pages 2-3)
• GI complaints: ~31% (ciaccio2017fragilexsyndrome pages 2-3)
• Strabismus: 30–55% (young males) (genovese2025systematicreviewfragile pages 6-7)

3.4 Developmental timing and progression

Developmental delay is typically recognized in infancy/early childhood (boys as early as ~6 months; girls ~1 year in a systematic review). (genovese2025systematicreviewfragile pages 7-9)

3.5 Quality-of-life impact

FXS-associated ASD features “emerge in early childhood and impair daily functioning,” and FXS can impair adaptive skills needed for communication, self-care, and social participation, consistent with substantial QOL impact. (de2025fromdiscoveryto pages 3-4)

3.6 Suggested HPO terms (best-effort, not extracted from evidence text)

These are standard phenotype mappings consistent with the reported clinical picture: - Intellectual disability (HP:0001249) - Global developmental delay (HP:0001263) - Autism (HP:0000717) - Seizures (HP:0001250) - Anxiety (HP:0000739) - Attention deficit hyperactivity disorder (HP:0007018) - Macroorchidism (HP:0000049) - Large ears (HP:0000400) - Strabismus (HP:0000486) - Sleep disturbance (HP:0002360)

4. Genetic / Molecular Information

4.1 Causal gene

• FMR1 (Xq27.3). (ciaccio2017fragilexsyndrome pages 1-2)

4.2 Pathogenic variant class

• Repeat expansion in the 5′UTR CGG tract is the dominant mechanism (>99% of cases in one review), with full mutation generally >200 repeats leading to methylation and silencing. (ciaccio2017fragilexsyndrome pages 1-2, de2025fromdiscoveryto pages 4-6)

4.3 Functional consequence

• Loss of function of FMR1 at the expression level (epigenetic silencing) leads to loss of FMRP. (de2025fromdiscoveryto pages 4-6, volianskis2024alterationsinsynaptic pages 15-19)

4.4 Modifier mechanisms

• Mosaicism (size or methylation mosaicism) contributes to variable FMRP expression and phenotype variability; mosaicism with partially unmethylated alleles is associated with better cognitive functioning. (genovese2025systematicreviewfragile pages 7-9, volianskis2024alterationsinsynaptic pages 15-19)

4.5 Epigenetic information

FXS full mutation is associated with hypermethylation of FMR1, transcriptional silencing, and heterochromatinization. (volianskis2024alterationsinsynaptic pages 15-19)

5. Environmental Information

FXS is primarily genetic. The retrieved evidence corpus did not provide specific validated environmental exposures that cause classic FXS (as opposed to modifying symptoms). Supportive-care and early intervention (environmental/behavioral supports) affect outcomes but are not etiologic.

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

1. FMR1 CGG full mutation (>200 repeats) in 5′UTR → 2. hypermethylation and chromatin silencing of FMR1 → 3. loss of FMRP (RNA-binding translational regulator) → 4. dysregulated transport/local translation of synaptic mRNAs and altered protein synthesis → 5. abnormal dendritic spine maturation (immature/elongated spines), altered synaptic plasticity and circuit function → 6. excitatory/inhibitory imbalance and hyperexcitability involving glutamatergic (mGluR5) and GABAergic systems → 7. neurodevelopmental phenotype (ID, ASD traits, behavioral dysregulation, seizures). (de2025fromdiscoveryto pages 4-6, volianskis2024alterationsinsynaptic pages 15-19)

6.2 Implicated pathways (examples)

• mGluR5 signaling dysregulation (loss of FMRP’s normal negative regulation) is emphasized as a major mechanistic framework. (de2025fromdiscoveryto pages 4-6)
• GABAergic deficits and E/I imbalance are repeatedly described. (de2025fromdiscoveryto pages 4-6)
• cAMP signaling abnormalities are noted in human cell lines and models, motivating PDE inhibition strategies. (genovese2025systematicreviewfragile pages 12-13)

6.3 Suggested GO biological process terms (best-effort)

• Synaptic signaling (GO:0099536)
• Regulation of translation (GO:0006417)
• Synaptic plasticity (GO:0048167)
• Dendritic spine development (GO:0060998)
• Regulation of excitatory postsynaptic potential (GO:0099528)

6.4 Suggested CL cell types (best-effort)

• Cortical pyramidal neuron (CL:0000540)
• GABAergic interneuron (CL:0000099)

6.5 Suggested UBERON anatomical structures (best-effort)

• Cerebral cortex (UBERON:0000956)
• Hippocampus (UBERON:0001954)
• Prefrontal cortex (UBERON:0001870)

6.6 Molecular profiling / biomarkers (selected)

• EEG-based translational biomarkers are emphasized as objective measures; BPN14770 studies specifically analyze auditory N1 ERP and peak alpha frequency (PAF) as treatment-linked physiology measures. (norris2024auditoryn1eventrelated pages 1-2, norris2025rocanalysisof pages 8-10)

7. Anatomical Structures Affected

Organ/system level

Primary involvement is the central nervous system with downstream behavioral, cognitive, and neuropsychiatric manifestations. (de2025fromdiscoveryto pages 4-6, de2025fromdiscoveryto pages 3-4)

Tissue/cell level

FXS pathophysiology is discussed in terms of synaptic dysfunction in neuronal circuits and altered excitatory/inhibitory balance (glutamatergic and GABAergic synapses). (de2025fromdiscoveryto pages 4-6, ntoulas2024multilevelprofilingof pages 1-2)

8. Temporal Development

Onset

Typically early (infancy/early childhood) with developmental delays. (genovese2025systematicreviewfragile pages 7-9)

Progression

FXS is generally described as not markedly worsening over time; however, males may show IQ decline during development/early puberty in some analyses. (genovese2025systematicreviewfragile pages 7-9, genovese2025systematicreviewfragile pages 2-4)

9. Inheritance and Population

9.1 Inheritance

• X-linked dominant inheritance pattern is described, with dynamic repeat expansion/anticipation, especially during maternal transmission. (genovese2025systematicreviewfragile pages 2-4, volianskis2024alterationsinsynaptic pages 15-19)

9.2 Epidemiology (selected statistics)

• Prevalence: ~1 in 4,000 males and 1 in 8,000 females (genovese2025systematicreviewfragile pages 2-4).
• Premutation carrier frequency: ~1 in 250 females and 1 in 800 males (premutation defined 55–200 repeats). (genovese2025systematicreviewfragile pages 2-4)

Newborn-screening derived incidence: In a population screen of 36,124 newborn males, 7 full-mutation FXS cases were confirmed, corresponding to an incidence of 1 in 5161 (95% CI 1/10,653–1/2500). (coffee2009incidenceoffragile media 983b62aa)

10. Diagnostics

10.1 Molecular diagnostic approach (current standard in retrieved sources)

• Postnatal testing often includes PCR combined with Southern blot and/or triplet-primed PCR (TP-PCR) to detect FMR1 repeat expansions and assess size. (genovese2025systematicreviewfragile pages 2-4)
• Because pathogenicity depends strongly on methylation/silencing, testing commonly includes methylation-sensitive methods. (genovese2025systematicreviewfragile pages 2-4)

10.2 Newborn screening / early detection

A newborn screening approach based on quantitative FMR1 methylation in dried blood spots was developed and used to directly measure incidence in a large male newborn cohort, supporting feasibility of early detection. (coffee2009incidenceoffragile media 983b62aa)

10.3 Prenatal diagnosis

Prenatal diagnostic options described include chorionic villus sampling and amniocentesis when there is family history or known carrier status. (genovese2025systematicreviewfragile pages 2-4)

10.4 Differential diagnosis

Not systematically extractable from the retrieved excerpts.

11. Outcome / Prognosis

FXS is generally not considered directly life-threatening and does not typically show marked neurodegenerative worsening as a primary feature, but it produces lifelong functional challenges requiring support. (genovese2025systematicreviewfragile pages 2-4)

Premutation carriers have distinct late-onset risks (e.g., FXTAS, FXPOI), but these are separate fragile X–associated disorders rather than classic full-mutation FXS. (genovese2025systematicreviewfragile pages 7-9, volianskis2024alterationsinsynaptic pages 15-19)

12. Treatment

12.1 Current clinical practice (real-world implementation)

No FDA-approved disease-modifying medications exist for FXS; management is largely symptom-based and multidisciplinary, including behavioral therapies, speech-language therapy, applied behavior analysis, parent training, and CBT to address communication and behavioral/psychiatric symptoms. (genovese2025systematicreviewfragile pages 10-12)

12.2 Recent clinical trial developments (2023–2024 prioritized)

Key recent peer-reviewed trials and translational biomarker papers: - AFQ056 (mavoglurant) FXLEARN trial (2024, JCI): 99 randomized young children; no benefit over placebo on primary WCS language outcome; strong example of translational gap for mGluR5 NAMs. (berrykravis2024effectsofafq056 pages 1-2, berrykravis2024effectsofafq056 pages 3-5) - Metformin longitudinal follow-up (2024, Frontiers in Psychology): open-label follow-up in n=26 (6–25 years) over 1–3 years; nonverbal IQ and adaptive function stable with no significant decline. (seng2024longitudinalfollowupof pages 3-4) - BPN14770 (zatolmilast) biomarker analysis (2024, Molecular Autism): N1 ERP amplitude correlated with serum drug concentration (rho=0.608, p=0.036 in period-1 drug recipients), supporting an exposure–physiology link; clinical improvements in cognition/language/daily functioning were reported in the trial background. (norris2024auditoryn1eventrelated pages 2-4, norris2024auditoryn1eventrelated pages 1-2)

12.3 Targeted/symptomatic agents with mixed evidence

Reviews summarize mixed/negative outcomes for multiple targeted approaches, with occasional subgroup signals: - Arbaclofen (GABA-B agonist): Phase 3 trials negative overall; some pediatric irritability benefits at higher doses. (protic2025targeteddrugdevelopment pages 4-5) - Ganaxolone (GABAA PAM): safe but primary endpoint negative overall; possible subgroup benefits. (protic2025targeteddrugdevelopment pages 4-5) - Gaboxadol (OV101): early signal with ~60% CGI-I responders in a small study summarized in reviews. (protic2025targeteddrugdevelopment pages 4-5) - Cannabidiol / ZYN002: phase 3 negative overall with post hoc methylation-defined subgroup benefit reported in a review summary. (protic2025razvojciljanefarmakoterapije pages 5-6)

A compact cross-intervention summary is provided below: | Intervention | Mechanism / target | Key study / design | Sample size / population | Primary endpoint(s) / main measures | Main findings reported | NCT ID(s) | Publication date | URL | Citation | |---|---|---|---|---|---|---|---|---|---| | AFQ056 (mavoglurant) | mGluR5 negative allosteric modulator | FXLEARN: large multisite randomized, double-blind, placebo-controlled trial with 4-month placebo lead-in, 2-month dose optimization, 6-month treatment; all participants also received parent-implemented language intervention | 110 enrolled; 99 randomized (50 AFQ056, 49 placebo); 91 completed placebo-controlled period; children age ~3–6 years with FXS | Primary: Weighted Communication Scale (WCS); secondary: objective and parent-reported cognitive/language measures including MSEL, PLS-5, Vineland-3 | No significant difference vs placebo on WCS or secondary measures; both groups improved in language over time; lower-baseline communication subgroup did worse on AFQ056 than placebo in subgroup analysis; no major safety signal | NCT02920892 | 2024-08 | https://doi.org/10.1172/jci171723 | (berrykravis2024effectsofafq056 pages 1-2, berrykravis2024effectsofafq056 pages 3-5, berrykravis2024effectsofafq056 pages 6-7, berrykravis2024effectsofafq056 pages 9-10) | | Metformin | AMPK activation; proposed reduction of MMP-9 / modulation of dysregulated signaling | Open-label longitudinal follow-up after prior controlled exposure; repeated cognitive and adaptive behavior testing over 1–3 years | 26 individuals with FXS (22 males, 4 females), ages 6–25 years | Leiter-III nonverbal IQ; Vineland-3 adaptive behavior | Overall nonverbal IQ and adaptive behavior remained stable; no significant decline over follow-up; small sample and no control group limit inference | NCT05120505 ongoing pediatric RCT also identified in registry; separate follow-up paper is open-label longitudinal | 2024-06 | https://doi.org/10.3389/fpsyg.2024.1305597 | (seng2024longitudinalfollowupof pages 1-2, seng2024longitudinalfollowupof pages 3-4, seng2024longitudinalfollowupof pages 2-3, NCT05120505 chunk 1) | | BPN14770 (zatolmilast) | PDE4D inhibitor; increases cAMP signaling | Phase 2a placebo-controlled crossover trial with EEG biomarker analyses; later exploratory ROC/EEG work | 30 adult males with FXS; EEG subsets smaller due to artifact/data loss | Clinical cognition/language/daily function measures; auditory N1 ERP amplitude; exploratory peak alpha frequency (PAF) | Clinical improvements in cognition, language, and daily functioning were reported; N1 amplitude showed correlation with serum drug concentration, stronger in period-1 drug recipients (rho = 0.608, p = 0.036, N = 12); exploratory PAF increased vs baseline and may be a scalable biomarker | NCT03569631 | 2024-11 (biomarker paper); 2025-05 (exploratory preprint) | https://doi.org/10.1186/s13229-024-00626-0 ; https://doi.org/10.1101/2025.05.29.25328581 | (norris2024auditoryn1eventrelated pages 1-2, norris2024auditoryn1eventrelated pages 2-4, norris2025rocanalysisof pages 1-4, norris2025rocanalysisof pages 8-10) | | Arbaclofen (STX209) | GABA-B agonist | Two Phase 3 placebo-controlled trials in children and in adolescents/adults | Pediatric and adult/adolescent cohorts; registry lists 172 children in NCT01325220 and 125 adolescents/adults in NCT01282268 | Primary behavioral/social withdrawal outcomes; irritability subscales and parent-rated outcomes reported in reviews | Overall primary endpoints not met; pediatric highest-dose group showed improvements on ABC-CFX Irritability and Parenting Stress Index / parent-rated forms; generally well tolerated | NCT01325220; NCT01282268 | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01325220 ; https://clinicaltrials.gov/study/NCT01282268 | (protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 9-10) | | Ganaxolone | GABAA positive allosteric modulator / neurosteroid | Phase 2 randomized crossover trial in children/adolescents | n = 59 in registry/review | Primary: CGI-I | Safe but did not differ from placebo on primary CGI-I endpoint overall; post hoc subgroup benefits reported in participants with higher anxiety or lower cognition | NCT01725152 | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01725152 | (protic2025targeteddrugdevelopment pages 4-5) | | Gaboxadol (OV101) | GABAA agonist / extrasynaptic GABAergic modulation | Phase 2a ROCKET study; additional recruiting single-dose adult study noted in review | ~23 participants in phase 2a response analysis | CGI-I and clinician/caregiver-rated behavioral measures | Well tolerated; about 60% classified as CGI-I responders in phase 2a; initial efficacy signal on hyperactivity, irritability, stereotypy, and anxiety in reported review summaries | NCT06334419 recruiting study noted; ROCKET NCT not provided in evidence excerpt | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://doi.org/10.3390/biomedicines13040805 | (protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 8-9) | | Cannabidiol / ZYN002 | Endocannabinoid system modulation; transdermal CBD formulation | Phase 1/2 open-label and Phase 3 CONNECT-FX reviewed; post hoc methylation-stratified analyses | Sample size not stated in provided evidence excerpt | ADAMS and phase 3 primary endpoint not specified in excerpt | Open-label study showed safety and ADAMS reduction; CONNECT-FX failed primary endpoint overall, but subgroup with ≥90% FMR1 promoter methylation showed benefit, motivating RECONNECT | NCT04977986 recruiting study noted in review | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://doi.org/10.3390/biomedicines13040805 | (protic2025razvojciljanefarmakoterapije pages 5-6, de2025fromdiscoveryto pages 8-9) | | Older mGluR5 program overview (mavoglurant / basimglurant) | mGluR5 negative allosteric modulation | Earlier adult/adolescent Phase 2/2b and extension trials summarized in reviews | Small crossover adult mavoglurant study in 30 adult males; larger adolescent/adult trials listed in reviews/registry | Behavioral endpoints; FXLEARN later used WCS for language learning in young children | Initial small subgroup signal in fully methylated cases did not replicate; larger Phase 2b trials and basimglurant Phase II studies were negative, contributing to skepticism about direct mGluR5 translation from animal models | NCT01357239; NCT01348087; NCT01433354; NCT02920892 | 2024-08 and 2025 review summaries | https://doi.org/10.1172/jci171723 ; https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01357239 | (berrykravis2024effectsofafq056 pages 1-2, protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 9-10) |

Table: This table summarizes key Fragile X syndrome therapeutic studies and trial programs emphasized in the gathered evidence, including recent 2024 findings and older targeted treatment programs. It is useful for comparing mechanisms, study designs, endpoints, outcomes, and trial identifiers across leading pharmacologic approaches.

12.4 Suggested MAXO terms (best-effort)

• Pharmacotherapy (MAXO:0000058)
• Behavioral therapy (MAXO:0000506)
• Speech therapy (MAXO:0001193)
• Genetic counseling (MAXO:0000070)

13. Prevention

Primary prevention

Because FXS is inherited, prevention focuses on genetic counseling and reproductive planning for carriers. (genovese2025systematicreviewfragile pages 2-4)

Secondary prevention (screening/early detection)

• Newborn screening by methylation assay in dried blood spots has been demonstrated and used to estimate incidence, supporting a potential early-intervention pathway. (coffee2009incidenceoffragile media 983b62aa)

Tertiary prevention

Multidisciplinary management and early developmental/behavioral interventions aim to reduce disability and improve long-term functioning. (genovese2025systematicreviewfragile pages 12-13, genovese2025systematicreviewfragile pages 10-12)

14. Other Species / Natural Disease

The retrieved evidence focuses on model organisms rather than naturally occurring veterinary disease. No naturally occurring non-human clinical syndrome analogous to human FXS was identified in the provided corpus.

15. Model Organisms

A diverse model ecosystem is used to study FMRP function and therapeutics: - Mouse (Fmr1 KO): dominant in vivo model; captures many phenotypes (immature spines, altered LTP/LTD, hyperactivity/anxiety/social changes); key limitations include species differences and differences in timing of FMRP expression vs humans (humans express FMR1 until at least week 10 gestation). (de2025fromdiscoveryto pages 6-8) - Rat (Fmr1 KO): proposed to offer added translational validity; a 2024 study combined behavior, hippocampal electrophysiology, and RNA-seq and found hyperactivity/cognitive deficits plus glutamatergic/GABAergic alterations in PFC and hippocampus. (ntoulas2024multilevelprofilingof pages 1-2) - Drosophila / zebrafish: useful for conserved genetics/pathway discovery; limitations include species differences. (sandoval2024fromwingsto pages 2-3) - Human iPSC neurons and 3D organoids/assembloids: enable study of patient-derived epigenetic FMR1 silencing and human-specific neurodevelopment; limitations include immaturity, reproducibility issues, and inability to model behavior. (sandoval2024fromwingsto pages 5-7)

Expert opinions / analysis (from authoritative sources in retrieved corpus)

A consistent expert view in recent reviews is that translation from strong preclinical signals to clinical efficacy has been limited by patient heterogeneity, inconsistent outcomes, and the need for objective biomarkers and better trial design—highlighted in the context of mGluR5 NAM programs and the field’s shift toward biomarkers (EEG), stratification (methylation status), and gene/reactivation strategies (ASOs, CRISPR-based approaches). (de2025fromdiscoveryto pages 18-19, de2025fromdiscoveryto pages 13-15, berrykravis2024effectsofafq056 pages 1-2)

Key recent statistics (selected)

• Prevalence: ~1/4,000 males and ~1/8,000 females. (genovese2025systematicreviewfragile pages 2-4)
• Premutation frequency: ~1/250 females; ~1/800 males. (genovese2025systematicreviewfragile pages 2-4)
• Newborn-screening incidence in males: 1/5,161 (7/36,124). (coffee2009incidenceoffragile media 983b62aa)
• Comorbid ASD in FXS: ~46% males and 16% females (“just over 40% overall”). (genovese2025systematicreviewfragile pages 7-9)
• Seizure prevalence: ~15–20% males and ~5% females (review estimate). (de2025fromdiscoveryto pages 4-6)

Limitations of this report (evidence availability)

1. Specific ontology identifiers (MONDO ID, Orphanet ORPHAcode, MeSH, ICD-10/ICD-11) were not present in the retrieved documents and thus could not be extracted with full citation support.
2. Some requested sections (environmental risk/protective factors, formal diagnostic criteria, differential diagnosis, survival statistics) were not explicitly quantified in the retrieved excerpts.
3. Suggested ontology term mappings (HPO/GO/CL/UBERON/MAXO) are provided as best-effort standard mappings rather than extracted identifiers from the cited texts.

References

1. (de2025fromdiscoveryto pages 4-6): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

2. (genovese2025systematicreviewfragile pages 2-4): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.

3. (de2025fromdiscoveryto pages 1-3): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

4. (coffee2009incidenceoffragile media 983b62aa): Bradford Coffee, Krayton Keith, Igor Albizua, Tamika Malone, Julie Mowrey, Stephanie L. Sherman, and Stephen T. Warren. Incidence of fragile x syndrome by newborn screening for methylated fmr1 dna. American journal of human genetics, 85 4:503-14, Oct 2009. URL: https://doi.org/10.1016/j.ajhg.2009.09.007, doi:10.1016/j.ajhg.2009.09.007. This article has 558 citations and is from a highest quality peer-reviewed journal.

5. (de2025fromdiscoveryto pages 3-4): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

6. (ciaccio2017fragilexsyndrome pages 1-2): Claudia Ciaccio, Laura Fontana, Donatella Milani, Silvia Tabano, Monica Miozzo, and Susanna Esposito. Fragile x syndrome: a review of clinical and molecular diagnoses. Italian Journal of Pediatrics, Apr 2017. URL: https://doi.org/10.1186/s13052-017-0355-y, doi:10.1186/s13052-017-0355-y. This article has 223 citations and is from a peer-reviewed journal.

7. (berrykravis2024effectsofafq056 pages 1-2): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.

8. (seng2024longitudinalfollowupof pages 1-2): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.

9. (volianskis2024alterationsinsynaptic pages 15-19): RE Volianskis. Alterations in synaptic plasticity in a mouse model of fragile x syndrome. Unknown journal, 2024.

10. (genovese2025systematicreviewfragile pages 7-9): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.

11. (ciaccio2017fragilexsyndrome pages 2-3): Claudia Ciaccio, Laura Fontana, Donatella Milani, Silvia Tabano, Monica Miozzo, and Susanna Esposito. Fragile x syndrome: a review of clinical and molecular diagnoses. Italian Journal of Pediatrics, Apr 2017. URL: https://doi.org/10.1186/s13052-017-0355-y, doi:10.1186/s13052-017-0355-y. This article has 223 citations and is from a peer-reviewed journal.

12. (genovese2025systematicreviewfragile pages 6-7): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.

13. (genovese2025systematicreviewfragile pages 12-13): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.

14. (norris2024auditoryn1eventrelated pages 1-2): Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, and Lauren E. Ethridge. Auditory n1 event-related potential amplitude is predictive of serum concentration of bpn14770 in fragile x syndrome. Molecular Autism, Nov 2024. URL: https://doi.org/10.1186/s13229-024-00626-0, doi:10.1186/s13229-024-00626-0. This article has 5 citations and is from a peer-reviewed journal.

15. (norris2025rocanalysisof pages 8-10): J. E. Norris, E. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Emma K. Auger Ph.D., Abigail H. Outterson Ph.D., Jeremiah Furman, Mark E. Gurney, and Ph.D Lauren E. Ethridge. Roc analysis of biomarker combinations in fragile x syndrome-specific clinical trials: evaluating treatment efficacy via exploratory biomarkers. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.29.25328581, doi:10.1101/2025.05.29.25328581. This article has 1 citations.

16. (ntoulas2024multilevelprofilingof pages 1-2): George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, Michail-Zois Asprogerakas, Foteini Delis, Leonidas J. Leontiadis, George Trompoukis, Costas Papatheodoropoulos, Dimitrios Gkikas, Dimitrios Valakos, Giannis Vatsellas, Panagiotis K. Politis, Alexia Polissidis, and Katerina Antoniou. Multi-level profiling of the fmr1 ko rat unveils altered behavioral traits along with aberrant glutamatergic function. Translational Psychiatry, Feb 2024. URL: https://doi.org/10.1038/s41398-024-02815-0, doi:10.1038/s41398-024-02815-0. This article has 10 citations and is from a peer-reviewed journal.

17. (genovese2025systematicreviewfragile pages 10-12): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.

18. (berrykravis2024effectsofafq056 pages 3-5): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.

19. (seng2024longitudinalfollowupof pages 3-4): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.

20. (norris2024auditoryn1eventrelated pages 2-4): Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, and Lauren E. Ethridge. Auditory n1 event-related potential amplitude is predictive of serum concentration of bpn14770 in fragile x syndrome. Molecular Autism, Nov 2024. URL: https://doi.org/10.1186/s13229-024-00626-0, doi:10.1186/s13229-024-00626-0. This article has 5 citations and is from a peer-reviewed journal.

21. (protic2025targeteddrugdevelopment pages 4-5): Dragana Protić, Maja Stojković, and Dejan Budimirović. Targeted drug development in fragile x syndrome: molecular medicine as a key tool in clinical pharmacology. Medicinska istrazivanja, pages 19-19, Jan 2025. URL: https://doi.org/10.5937/medi0-60213, doi:10.5937/medi0-60213. This article has 0 citations.

22. (protic2025razvojciljanefarmakoterapije pages 5-6): D Protic, M Stojkovic, and D Budimirovic. Razvoj ciljane farmakoterapije za fragilni x sindrom: molekularna medicina kao ključno sredstvo u kliničkoj …. Unknown journal, 2025.

23. (berrykravis2024effectsofafq056 pages 6-7): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.

24. (berrykravis2024effectsofafq056 pages 9-10): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.

25. (seng2024longitudinalfollowupof pages 2-3): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.

26. (NCT05120505 chunk 1): Metformin in Children With Fragile X Syndrome. Children's Hospital of Fudan University. 2021. ClinicalTrials.gov Identifier: NCT05120505

27. (norris2025rocanalysisof pages 1-4): J. E. Norris, E. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Emma K. Auger Ph.D., Abigail H. Outterson Ph.D., Jeremiah Furman, Mark E. Gurney, and Ph.D Lauren E. Ethridge. Roc analysis of biomarker combinations in fragile x syndrome-specific clinical trials: evaluating treatment efficacy via exploratory biomarkers. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.29.25328581, doi:10.1101/2025.05.29.25328581. This article has 1 citations.

28. (de2025fromdiscoveryto pages 9-10): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

29. (de2025fromdiscoveryto pages 8-9): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

30. (de2025fromdiscoveryto pages 6-8): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

31. (sandoval2024fromwingsto pages 2-3): Soraya O. Sandoval, Natasha M. Méndez-Albelo, Zhiyan Xu, and Xinyu Zhao. From wings to whiskers to stem cells: why every model matters in fragile x syndrome research. Journal of Neurodevelopmental Disorders, Jun 2024. URL: https://doi.org/10.1186/s11689-024-09545-w, doi:10.1186/s11689-024-09545-w. This article has 3 citations and is from a peer-reviewed journal.

32. (sandoval2024fromwingsto pages 5-7): Soraya O. Sandoval, Natasha M. Méndez-Albelo, Zhiyan Xu, and Xinyu Zhao. From wings to whiskers to stem cells: why every model matters in fragile x syndrome research. Journal of Neurodevelopmental Disorders, Jun 2024. URL: https://doi.org/10.1186/s11689-024-09545-w, doi:10.1186/s11689-024-09545-w. This article has 3 citations and is from a peer-reviewed journal.

33. (de2025fromdiscoveryto pages 18-19): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

34. (de2025fromdiscoveryto pages 13-15): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.